Diamonds and Dogs
Shareholders at Allergan (AGN) are smiling. The biotech known for their famous Botox drug is up over 3% thanks to an upgrade at Morgan Stanley. Allergan is having a tough fall season down 30% from the summer highs, but the analyst at Morgan said the worst may be over and the shares have gotten too cheap to ignore following disappointing earnings and lowered expectations.
Not a good day for tech. The number one sector year to date is taking it on the chin today down 2% as the FAANG stocks are all down over 2%. Cloud computing software maker, Autodesk (ADSK) is down 15% to a two month low following earnings. The earnings were actually better than expected, but lowered subscription adds going forward and plans to cut 1,150 jobs, or 13% of its workforce, as it shifts focus to selling its products on a subscription basis instead of mostly charging for them upfront.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.